Mabwell announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-mab, has been formally approved for marketing by the National Medical Products Administration (NMPA) (Approval No.: S20233111). MAILISHU is the world's second approved Biosimilars of Denosumab for the osteoporosis in postmenopausal women at high risk of fracture. The drug can significantly reduce the risk of vertebral, non-vertebral and hip fractures within this patient segment.

The Marketing Center of Mabwell has mapped MAILISHU's launched plan since Fourth Quarter,2022 and optimizing continuously product promotion strategies and resource allocation plans by researching on the treatment field, patient composition, market potential and other aspects. It is expected that more than 200 hospitals will be accessed and sales goal will not be less than 300K units. Age related diseases are Mabwell's priority areas.

Mabwell has 17 pipeline products in different R&D stages based on a world-class and R&D engine, including 13 novel drug candidates and 4 biosimilars. The company focus on the therapeutic areas of auto-immune diseases, oncology, metabolic disorders, othalmologic diseases and infectious diseases, etc. Of these, 2 products has been approved and commercialized, 1 product have been filed for MA approval, 3 products are in pivotal trials.

The company have also undertaken 1 national major scientific and technological special project for "Sign Significant New Drugs Development", 2 projects for National Key R&D Programs, and several provincial and municipal science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction.